4CPS-263 Case report of Kawasaki disease and SARS-CoV-2 infection in a paediatric hospital

Abstract

2% immunomodulation cases and the remaining 8.5% were off-label (of these, 64% had probable benefit). The most prevalent indications were chronic inflammatory demyelinating polyradiculopathy (39%) and MyD88 deficiency (31%). Doses and IR were as indicated. There were recorded AR. IVIG accounted for 1.21% of the institution's total medication expenses. Conclusion and relevance IVIG was mostly used for approved indications. Doses and IR were within the recommended range and no AR were reported, suggesting that the administrations was well tolerated. Off-label use, although characterised by limited expression and for indications with probable benefit, included indications not mentioned in the guidance. In this study, hospital prescriptions showed a low level of compliance with the NPTC guidance; therefore, an institutional protocol should be developed for a more evidence based approach to IVIG use. Locally, the annual expenses for IVIG (1.21%), a value way below the national average (2.83%), may be due to the smaller size and complexity of the hospital and slight offlabel use. REFERENCES AND/OR ACKNOWLEDGEMENTS 1. Comissão Nacional de Farmácia/Terapêutica. (2020). Recomendação sobre utilização de IgHN. Orientações Comissão Nacional Farmácia/Terapêutica.